bibliografía

Walsh KB, McKinney AE and Holmes AE (2021) Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses. Front. Pharmacol. 12:777804. doi: 10.3389/fphar.2021.777804

Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., et al. (1990). Cannabinoid Receptor Localization in Brain. Proc. Natl. Acad. Sci. U S A. 87, 1932–1936. doi:10.1073/pnas.87.5.1932

Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., and Walker, J. M. (1998). Immunohistochemical Distribution of Cannabinoid CB1 Receptors in the Rat central Nervous System. Neuroscience 83, 393–411. doi:10.1016/s0306- 4522(97)00436-3

Munro, S., Thomas, K. L., and Abu-Shaar, M. (1993). Molecular Characterization of a Peripheral Receptor for Cannabinoids. Nature 365, 61–65. doi:10.1038/ 365061a0

Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., et al. (1995). Expression of central and Peripheral Cannabinoid Receptors in Human Immune Tissues and Leukocyte Subpopulations. Eur. J. Biochem. 232, 54–61. doi:10.1111/j.1432-1033.1995.tb20780.x

Stella, N. (2010). Cannabinoid and Cannabinoid-like Receptors in Microglia, Astrocytes, and Astrocytomas. Glia 58, 1017–1030. doi:10.1002/glia.20983

Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., et al. (1992). Isolation and Structure of a Brain Constituent that Binds to the Cannabinoid Receptor. Science 258, 1946–1949. doi:10.1126/science.1470919

Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., et al. (1995). Identification of an Endogenous 2-monoglyceride, Present in Canine Gut, that Binds to Cannabinoid Receptors. Biochem. Pharmacol. 50, 83–90. doi:10.1016/0006-2952(95)00109-d

Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., et al. (1995). 2-Arachidonoylglycerol: a Possible Endogenous Cannabinoid Receptor Ligand in Brain. Biochem. Biophys. Res. Commun. 215, 89–97. doi:10.1006/ bbrc.1995.2437

Hanus, L. O., Meyer, S. M., Muñoz, E., Taglialatela-Scafati, O., and Appendino, G. (2016). Phytocannabinoids: a Unified Critical Inventory. Nat. Prod. Rep. 33, 1357–1392

Gülck, T., and Möller, B. L. (2020). Phytocannabinoids: Origins and Biosynthesis. Trends Plant Sci. 25, 985-1004

Pain, S. A potted history. Nature 2015, 525, S10–S11

Paredes, D.A.; Catlow, B.J.; Sanchez-Ramos, J. 402C14 The Endocannabinoid System in the Aging Brain and Neurodegenerative Diseases. In Integrative Neurology; McBurney, J.W., Ruhoy, I.S., Weil, A.T., Eds.; Oxford University Press: Oxford, UK, 2020.

Duczmal, D.; Bazan-Wozniak, A.; Niedzielska, K.; Pietrzak, R. Cannabinoids— Multifunctional Compounds, Applications and Challenges—Mini Review. Molecules 2024, 29, 4923. https://doi.org/10.3390/ molecules29204923

Jin D, Dai K, Xie Z, Chen J. Secondary Metabolites Profiled in Cannabis Inflorescences, Leaves, Stem Barks, and Roots for Medicinal Purposes. Sci Rep. 2020 Feb 24;10(1):3309. doi: 10.1038/s41598-020-60172-6. PMID: 32094454; PMCID: PMC7039888

Ben-Shabat, S.; Fride, E.; Sheskin, T.; Tamiri, T.; Rhee, M.-H.; Vogel, Z.; Bisogno, T.; De Petrocellis, L.; Di Marzo, V.; Mechoulam, R. An Entourage Effect: Inactive Endogenous Fatty Acid Glycerol Esters Enhance 2-Arachidonoyl-Glycerol Cannabinoid Activity. Eur. J. Pharmacol. 1998, 353, 23–31

André, R.; Gomes, A.P.; Pereira-Leite, C.; Marques-da-Costa, A.; Monteiro Rodrigues, L.; Sassano, M.; Rijo, P.; Costa, M.d.C. The Entourage Effect in Cannabis Medicinal Products: A Comprehensive Review. Pharmaceuticals 2024, 17, 1543. doi.org/10.3390/ph17111543

Mechoulam R, Ben-Shabat S. From Gan-Zi-Gun-Nu to Anandamide and 2 arachidonoylglycerol: The ongoing story of cannabis. Nat Prod Rep 1999; 16(2):131–143; doi: 10.1039/a703973e

Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011; 163(7):1344–1364

Almog S, Aharon-Peretz J, Vulfsons S, et al. The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial. Eur J Pain. 2020; 24: 1505- 1516. doi.org/10.1002/ejp.160

Billman GE (2020) Homeostasis: The Underappreciated and Far Too Often Ignored Central Organizing Principle of Physiology. Front. Physiol. 11:200. doi: 10.3389/fphys.2020.00200

Dallabrida KG, de Oliveira Bender JM, Chade ES, Rodrigues N, Sampaio TB. Endocannabinoid System Changes throughout Life: Implications and Therapeutic Potential for Autism, ADHD, and Alzheimer's Disease. Brain Sci. 2024 Jun 10;14(6):592. doi: 10.3390/brainsci14060592. PMID: 38928592; PMCID: PMC11202267

Basavarajappa BS, Subbanna S. Unveiling the Potential of Phytocannabinoids: Exploring Marijuana's Lesser-Known Constituents for Neurological Disorders. Biomolecules. 2024 Oct 13;14(10):1296. doi: 10.3390/biom14101296. PMID: 39456229; PMCID: PMC11506053

Bonini SA, Premoli M, Tambaro S, Kumar A, Maccarinelli G, Memo M, Mastinu A. Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. J Ethnopharmacol. 2018 Dec 5;227:300-315. doi: 10.1016/j.jep.2018.09.004. Epub 2018 Sep 8. PMID: 30205181.

Zhang SS, Zhang NN, Guo TT, Sheen LY, Ho CT, Bai NS. The impact of phyto- and endo-cannabinoids on central nervous system diseases：A review. J Tradit Complement Med. 2022 Oct 12;13(1):30-38. doi: 10.1016/j.jtcme.2022.10.004. PMID: 36685079; PMCID: PMC9845650.

Bellnier T, Brown GW, Ortega TR. Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis. Ment Health Clin. 2018 Apr 26;8(3):110-115. doi: 10.9740/mhc.2018.05.110. PMID: 29955555; PMCID: PMC6007634.

Romero-Sandoval EA, Fincham JE, Kolano AL, Sharpe BN, Alvarado-Vázquez PA. Cannabis for Chronic Pain: Challenges and Considerations. Pharmacotherapy. 2018 Jun;38(6):651-662. doi: 10.1002/phar.2115. Epub 2018 May 16. PMID: 29637590.

Cifuentes M, Verdejo HE, Castro PF, Corvalan AH, Ferreccio C, Quest AFG, Kogan MJ, Lavandero S. Low-Grade Chronic Inflammation: a Shared Mechanism for Chronic Diseases. Physiology (Bethesda). 2025 Jan 1;40(1):0. doi: 10.1152/physiol.00021.2024. Epub 2024 Jul 30. PMID: 39078396.

A.M. Castro, L.E. Macedo-de la Concha, C.A. Pantoja-Meléndez, Low-grade inflammation and its relation to obesity and chronic degenerative diseases. Revista Médica del Hospital General de México,Volume 80, Issue 2,2017,Pages 101-105,ISSN 0185-1063, doi.org/10.1016/j.hgmx.2016.06.011.

Russo, Ethan B. The solution to the medicinal cannabis problem. En Ethical issues in chronic pain management. CRC Press, 2016. p. 165-194.

Russo, Ethan. Future of cannabis and cannabinoids in therapeutics. Journal of Cannabis Therapeutics, 2004, vol. 3, no 4, p. 163-174.

Smith, Steele Clarke; WAGNER, Mark S. Clinical endocannabinoid deficiency (CECD) revisited. Neuroendocrinology Letters, 2014, vol. 35, no 3.

Maldonado R, Cabañero D, Martín-García E. The endocannabinoid system in modulating fear, anxiety, and stress
. Dialogues Clin Neurosci. 2020 Sep;22(3):229-239. doi: 10.31887/DCNS.2020.22.3/rmaldonado. PMID: 33162766; PMCID: PMC7605023

Wu Y, Lan Y, Mao J, Shen J, Kang T, Xie Z. The interaction between the nervous system and the stomatognathic system: from development to diseases. Int J Oral Sci. 2023 Aug 15;15(1):34. doi: 10.1038/s41368-023-00241-4. Erratum in: Int J Oral Sci. 2023 Sep 11;15(1):39. doi: 10.1038/s41368-023-00250-3. PMID: 37580325; PMCID: PMC10425412.

Kalinowski, J.; Ahsan, T.; Ayed, M.; Esposito, M.M. The Relationship Between Neuropsychiatric Disorders and the Oral Microbiome. Bacteria 2025, 4, 30. https://doi.org/10.3390/bacteria4030030